

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

16314
Docket No.
✓ Army 140

In Re Application Of: Ulrich et al.

#36
Plunkett
5/17/03

Serial No.
08/882,431

Filing Date
June 25, 1997

Examiner
Allen, M.

Group Art Unit
1631

Title: Bacterial Superantigen Vaccines

RECEIVED

APR 24 2003

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

37 CFR 1.97(b)

1. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☒ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☒ the fee set forth in 37 CFR 1.17(p).

04/23/2003 DEHHANU1 00000078 210380 08882431
01 FC:1806 180.00 CH

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
Army 140

In Re Application: Ulrich et al.

Serial No.
08/882,431

Filing Date
June 25, 1997

Examiner
Allen, M.

Group Art Unit
1631

Bacterial Superantigen Vaccines

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$180.00
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited
Apr. 16, 2003 with the U.S. Postal Service
as first class mail under 37 C.F.R. 1.8 and is
addressed to the Assistant Commissioner for Patents,
Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Marlana Titus

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated: April 16, 2003


Marlana Titus, Reg. No. 35,843
for Elizabeth Arwine, Reg. No. 45,867
Attorney for applicant
U.S. Army Medical Research and Materiel Command
504 Scott St.
Ft. Detrick, MD 21702-5012
(301) 762-8214

cc:

RECEIVED

APR 24 2003

TECH CENTER 1600/2900



INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Docket Number (Optional)

Army140

Application Number

08/882,431

Applicant(s)

Ulrich et al.

Filing Date

June 25, 1997

Group Art Unit

1631

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

A

Bavari et al., "Engineered Bacterial Superantigen Vaccines", Vaccines 96, pages 135-141 (1996).

B

Bavari et al., "Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of Staphylococcal Enterotoxin A", J. Infectious Diseases, 1996, 174:338-345.

C

Hurley et al., "Identification of Class II Major Histocompatibility Complex and T Cell Receptor Binding Sites in the Superantigen Toxic Shock Syndrome Toxin 1", J. Exp. Med., Vol. 181, 2229-2235, June 1995.

D

Stiles, et al., "Toxicity of Staphylococcal Enterotoxins Potentiated by Lipopolysaccharide: Major Histocompatibility Complex Class II Molecule Dependency and Cytokine Release", Infection and Immunity, Vol. 61, No. 12, pages 5333-5338, Dec. 1993.

RECEIVED

APR 24 2003

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.